The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group,
Inc.: Nektar Therapeutics, Inc 11-Oct-2022 / 14:01 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS
Group. The issuer is solely responsible for the content of this
announcement.
-----------------------------------------------------------------------------------------------------------------------
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: The Vanguard Group,
Inc.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor
and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Nektar
Therapeutics, Inc.
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken:
7 October 2022
For an opening position disclosure, state the latest practicable date prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any
other party to the offer? PureTech Health plc
If it is a cash offer or possible cash offer, state "N/A"
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing (if any)
USD 0.0001 common
Class of relevant security:
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 23,156,390 12.32%
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
23,156,390 12.32%
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
(b) Rights to subscribe for new securities (including directors'
and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1 (c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Purchase/sale
Class of relevant security Number of securities Price per unit
USD 0.0001 common
Sale 1,507 3.53 USD
USD 0.0001 common
Purchase 23,494 3.53 USD
(b) Cash-settled derivative transactions
Product Nature of dealing
Class of relevant description Number of reference Price per
security e.g. opening/closing a long/short position, increasing/ securities unit
e.g. CFD reducing a long/short position
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Type
Class of Product Writing, Number of securities Exercise Option money
relevant description e.g. purchasing, to which option price per e.g. Expiry paid/ received
security call option selling, varying relates unit American, date per unit
etc. European
etc.
(ii) Exercise
Class of relevant Product description Exercising/ exercised
security against Number of securities Exercise price per unit
e.g. call option
(d) Other dealings (including subscribing for new
securities)
Nature of dealing
Class of relevant security Details Price per unit (if applicable)
e.g. subscription, conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to
relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the
disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or
understandings, state "none"
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure
and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is
referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 11 October 2022
Contact name: Shawn Acker
Telephone number: 001-610-669-8989
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
-----------------------------------------------------------------------------------------------------------------------
Category Code: RET - Nektar Therapeutics, Inc
TIDM:
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 193705
EQS News ID: 1461019
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1461019&application_name=news
(END) Dow Jones Newswires
October 11, 2022 09:01 ET (13:01 GMT)
Nektar Therapeutics (LSE:0UNL)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Nektar Therapeutics (LSE:0UNL)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
